Sight Sciences Inc

NASDAQ:SGHT   3:30:50 PM EDT
13.75
-1.10 (-7.41%)
Products

Sight Sciences Receives FDA 510(K) Clearance Of The Tearcare System For Treatment Of Meibomian Gland Dysfunction (Mgd), The Leading Cause Of Dry Eye Disease

Published: 12/22/2021 13:20 GMT
Sight Sciences Inc (SGHT) - Sight Sciences Receives FDA 510(k) Clearance of the Tearcare® System for Treatment of Meibomian Gland Dysfunction (mgd), the Leading Cause of Dry Eye Disease.